As an individual that's currently suffering from C-PTSD and depression, I believe that the benefits of AI-assisted medicine research could be immense if done in a safe and effective manner.
In this post, I am going to share and discuss some promising preliminary ideas to address the 2026 era bottlenecks and difficulties surrounding producing better psychiatric medicine, including via AI-assisted methods in the present and near future.
Idea 1: Better Hardware Protocols for Automated Lab Operation
Anthropic’s Model Hardware Standard is an early example. Its purpose is to give heterogeneous instruments a common description of their available states and procedures, allowing an AI system to control them without bespoke programming for every device. This seems promising for integrating the myriad of single-purpose legacy equipment that's commonplace in modern scientific laboratories.
More capable lab automation would be dual-use in nature: when a single-scientist team could produce promising pre-clinical trial drugs in his garage, it would be similarly reasonable to assume that a motivated and reasonably intelligent bad actor would be able to produce lethal chemicals in their backyard. Just because the current track record of bio-terrorists is poor doesn't mean that we should naively assume agentic AI systems would continue to cause relatively little biorisk in the future.
Therefore, a safety-oriented implementation could have every action be recorded in an auditable local log and periodically uploaded to the cloud. Even if we assume that the attacker would possess open source hardware or jailbroken hardware with such firmware removed, better stateful logging embedded in the hardware of biochemical synthesis companies could still allow defenders to use agentic AI to better monitor for misuse if an attacker decides to enter larger scale batch production.
Idea 2: Accessible Online Scientific Datasets for Agents
One of the most promising areas for AI-assisted research would be large-scale generation of promising new hypothesis for us to investigate. Examples of such systems are increasinglyplentiful. However, decades of papers were not digitized in a manner that's easy for agentic systems to view and interpret. For example, it is commonplace in some publication venues for the raw datasets behind graphs presented in papers to not be easily accessible via a downloadable endpoint.
When chart data is not directly downloadable, agents often "eyeball" for it - as I have observed in my own Codex usage with GPT-5.6-Sol when trying to, for example, get precise data points for the physical properties of Jell-O in order to conduct a simulation. The model is smart enough to know how to retrieve the paper, but still relies on viewing the image of the chart, which could leave room for serious error.
If AI swarms become large enough in operational scale, even carefully collected data from scattered individual papers might become inefficient to retrieve. Data endpoint providers creating carefully harmonized large-scale datasets that combine the data of papers with shared themes is an interesting direction worth further investigation on.
Idea 3: Improve Clinically Relevant Evidence Bandwidth via the Online Community
An emergent trend is that Erowid, PsychonautWiki, and other crowd-sourced drug use self-report communities with subjective effect reporting standards and longitudinal "retrospectives" are increasingly considered to be useful for finding insights with potential clinical significance that are worth investigating[1].
Many individuals had turned to Research Chemical vendors to supply them with promising new drugs. An example is Tabernanthalog, a non-hallucinogenic plastogen that passed Phase 1 trials, developed by Delix Therapeutics. Reports surfaced that Research Chemical vendors are selling Tabernanthalog to users that are interested in the drug (because it's in roughly the same class as serotonergic hallucinogens such as psilocybin and DMT, of which possesses unique antidepressant properties).
It is evident that the online evidence from reddit and discord (such as the ones aggregated in an article here) are insufficiently rigorous. For example, these reports don't have timestamped rigorous subjective effect documentation. Instead of making these users have to rely on Reddit, existing trusted non-profit usage report sites such as Erowid could expand on their catalogue of drugs to include a range of pre-clinical drugs that individuals are already self-administering today.
(As far as I know, Erowid is chronically funding constrained, leaving it in a rough position to accomodate for such changes, and the financial troubles also bottlenecked their user submission review process and technical development of their science community-facing services.)
A better organized collection of online self-report communities could greatly improve data about the risk profiles and clinical properties of especially interesting psychiatric medications and non-patented psychoactive substances. Treating high quality self reports as detailed qualitative reviews is a useful mental model here. (if you don't believe me, there are some genuinely[2] great [3]reports out on that site!)
Final Thoughts
The view taken by many onlookers historically was a pessimistic one: psych med development is widely regarded a graveyard of false starts and rough pass rates. But with better equipment, data, and community epistemology, there is reason to believe that AI could tractably uplift this field.
These also seem like plausible targets for philanthropy and the development of shared standards! People interested in helping are encouraged to investigate existing initiatives and contribute either funding or technical work.
As an individual that's currently suffering from C-PTSD and depression, I believe that the benefits of AI-assisted medicine research could be immense if done in a safe and effective manner.
In this post, I am going to share and discuss some promising preliminary ideas to address the 2026 era bottlenecks and difficulties surrounding producing better psychiatric medicine, including via AI-assisted methods in the present and near future.
Idea 1: Better Hardware Protocols for Automated Lab Operation
Anthropic’s Model Hardware Standard is an early example. Its purpose is to give heterogeneous instruments a common description of their available states and procedures, allowing an AI system to control them without bespoke programming for every device. This seems promising for integrating the myriad of single-purpose legacy equipment that's commonplace in modern scientific laboratories.
More capable lab automation would be dual-use in nature: when a single-scientist team could produce promising pre-clinical trial drugs in his garage, it would be similarly reasonable to assume that a motivated and reasonably intelligent bad actor would be able to produce lethal chemicals in their backyard. Just because the current track record of bio-terrorists is poor doesn't mean that we should naively assume agentic AI systems would continue to cause relatively little biorisk in the future.
Therefore, a safety-oriented implementation could have every action be recorded in an auditable local log and periodically uploaded to the cloud. Even if we assume that the attacker would possess open source hardware or jailbroken hardware with such firmware removed, better stateful logging embedded in the hardware of biochemical synthesis companies could still allow defenders to use agentic AI to better monitor for misuse if an attacker decides to enter larger scale batch production.
Idea 2: Accessible Online Scientific Datasets for Agents
One of the most promising areas for AI-assisted research would be large-scale generation of promising new hypothesis for us to investigate. Examples of such systems are increasingly plentiful. However, decades of papers were not digitized in a manner that's easy for agentic systems to view and interpret. For example, it is commonplace in some publication venues for the raw datasets behind graphs presented in papers to not be easily accessible via a downloadable endpoint.
When chart data is not directly downloadable, agents often "eyeball" for it - as I have observed in my own Codex usage with GPT-5.6-Sol when trying to, for example, get precise data points for the physical properties of Jell-O in order to conduct a simulation. The model is smart enough to know how to retrieve the paper, but still relies on viewing the image of the chart, which could leave room for serious error.
If AI swarms become large enough in operational scale, even carefully collected data from scattered individual papers might become inefficient to retrieve. Data endpoint providers creating carefully harmonized large-scale datasets that combine the data of papers with shared themes is an interesting direction worth further investigation on.
Idea 3: Improve Clinically Relevant Evidence Bandwidth via the Online Community
An emergent trend is that Erowid, PsychonautWiki, and other crowd-sourced drug use self-report communities with subjective effect reporting standards and longitudinal "retrospectives" are increasingly considered to be useful for finding insights with potential clinical significance that are worth investigating[1].
Many individuals had turned to Research Chemical vendors to supply them with promising new drugs. An example is Tabernanthalog, a non-hallucinogenic plastogen that passed Phase 1 trials, developed by Delix Therapeutics. Reports surfaced that Research Chemical vendors are selling Tabernanthalog to users that are interested in the drug (because it's in roughly the same class as serotonergic hallucinogens such as psilocybin and DMT, of which possesses unique antidepressant properties).
It is evident that the online evidence from reddit and discord (such as the ones aggregated in an article here) are insufficiently rigorous. For example, these reports don't have timestamped rigorous subjective effect documentation. Instead of making these users have to rely on Reddit, existing trusted non-profit usage report sites such as Erowid could expand on their catalogue of drugs to include a range of pre-clinical drugs that individuals are already self-administering today.
(As far as I know, Erowid is chronically funding constrained, leaving it in a rough position to accomodate for such changes, and the financial troubles also bottlenecked their user submission review process and technical development of their science community-facing services.)
A better organized collection of online self-report communities could greatly improve data about the risk profiles and clinical properties of especially interesting psychiatric medications and non-patented psychoactive substances. Treating high quality self reports as detailed qualitative reviews is a useful mental model here. (if you don't believe me, there are some genuinely[2] great [3]reports out on that site!)
Final Thoughts
The view taken by many onlookers historically was a pessimistic one: psych med development is widely regarded a graveyard of false starts and rough pass rates. But with better equipment, data, and community epistemology, there is reason to believe that AI could tractably uplift this field.
These also seem like plausible targets for philanthropy and the development of shared standards! People interested in helping are encouraged to investigate existing initiatives and contribute either funding or technical work.
https://ojs.aaai.org/index.php/ICWSM/article/view/19325
https://erowid.org/experiences/exp.php?ID=93801
https://erowid.org/experiences/exp.php?ID=9473